Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Standard
Implementing liquid biopsies into clinical decision making for cancer immunotherapy. / Quandt, Dagmar; Dieter Zucht, Hans; Amann, Arno; Wulf-Goldenberg, Anne; Borrebaeck, Carl; Cannarile, Michael; Lambrechts, Diether; Oberacher, Herbert; Garrett, James; Nayak, Tapan; Kazinski, Michael; Massie, Charles; Schwarzenbach, Heidi; Maio, Michele; Prins, Robert; Wendik, Björn; Hockett, Richard; Enderle, Daniel; Noerholm, Mikkel; Hendriks, Hans; Zwierzina, Heinz; Seliger, Barbara.
in: ONCOTARGET, Jahrgang 8, Nr. 29, 18.07.2017, S. 48507-48520.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Implementing liquid biopsies into clinical decision making for cancer immunotherapy
AU - Quandt, Dagmar
AU - Dieter Zucht, Hans
AU - Amann, Arno
AU - Wulf-Goldenberg, Anne
AU - Borrebaeck, Carl
AU - Cannarile, Michael
AU - Lambrechts, Diether
AU - Oberacher, Herbert
AU - Garrett, James
AU - Nayak, Tapan
AU - Kazinski, Michael
AU - Massie, Charles
AU - Schwarzenbach, Heidi
AU - Maio, Michele
AU - Prins, Robert
AU - Wendik, Björn
AU - Hockett, Richard
AU - Enderle, Daniel
AU - Noerholm, Mikkel
AU - Hendriks, Hans
AU - Zwierzina, Heinz
AU - Seliger, Barbara
PY - 2017/7/18
Y1 - 2017/7/18
N2 - During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies.Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.
AB - During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies.Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.
KW - Animals
KW - Biomarkers, Tumor
KW - Clinical Decision-Making
KW - Diagnostic Imaging
KW - Humans
KW - Immunotherapy
KW - Liquid Biopsy
KW - Neoplasms
KW - Journal Article
KW - Review
U2 - 10.18632/oncotarget.17397
DO - 10.18632/oncotarget.17397
M3 - SCORING: Review article
C2 - 28501851
VL - 8
SP - 48507
EP - 48520
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 29
ER -